Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE]

Trial Profile

PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE]

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Jan 2019

At a glance

  • Drugs Cabozantinib (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms PDIGREE
  • Most Recent Events

    • 03 Jan 2019 Status changed from planning to not yet recruiting.
    • 01 May 2017 According to an Exelixis media release, this trial is expected to start later in 2017.
    • 01 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top